Published in J Transl Med on March 04, 2011
Study of High-Dose Intravenous (IV) Vitamin C Treatment in Patients With Solid Tumors | NCT00441207
Pilot Trial of Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma (NHL) | NCT00626444
Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer | NCT00954525
Vitamin C as an Anti-cancer Drug | NCT01080352
Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease | NCT01125449
Ascorbate supplementation inhibits growth and metastasis of B16FO melanoma and 4T1 breast cancer cells in vitamin C-deficient mice. Int J Oncol (2012) 1.04
HIF-1α restricts NF-κB-dependent gene expression to control innate immunity signals. Dis Model Mech (2014) 0.80
Praziquantel synergistically enhances paclitaxel efficacy to inhibit cancer cell growth. PLoS One (2012) 0.76
Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy. J Transl Med (2014) 0.76
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med (1992) 20.79
Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A (1976) 4.89
Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol (2010) 4.83
HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell (2007) 4.81
Modulation of the antitumor immune response by complement. Nat Immunol (2008) 4.53
Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res (2001) 4.49
Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci U S A (1996) 4.45
The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci (2008) 4.40
Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med (2004) 4.30
Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med (2003) 4.04
The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact (1974) 3.91
Narrative review: the systemic capillary leak syndrome. Ann Intern Med (2010) 3.71
High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med (1985) 3.36
Pathophysiology of polytrauma. Injury (2005) 3.33
Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol (2009) 3.23
NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol (2006) 3.15
CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J Immunol (2006) 3.15
Effect of acute and chronic ascorbic acid on flow-mediated dilatation with sedentary and physically active human ageing. J Physiol (2004) 2.75
Vitamins E and C are safe across a broad range of intakes. Am J Clin Nutr (2005) 2.72
Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci U S A (2007) 2.71
Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res (1992) 2.64
Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med (1979) 2.63
Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost (2003) 2.59
Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A (2008) 2.50
Marked decrease in plasma antioxidants in aged osteoporotic women: results of a cross-sectional study. J Clin Endocrinol Metab (2003) 2.27
TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol (2004) 2.11
TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J Immunol (2006) 2.05
High mobility group 1 B-box mediates activation of human endothelium. J Intern Med (2003) 2.00
Randomized, prospective trial of antioxidant supplementation in critically ill surgical patients. Ann Surg (2002) 1.92
Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One (2010) 1.92
Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation. Int J Cardiol (2005) 1.89
Mechanisms for the role of tetrahydrobiopterin in endothelial function and vascular disease. Clin Sci (Lond) (2007) 1.87
The role of nitric oxide in cardiovascular diseases. Mol Aspects Med (2005) 1.86
Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest (1996) 1.86
Innate immunity and inflammation: a transcriptional paradigm. Immunol Res (2001) 1.73
Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care (2005) 1.73
The association of endothelial cell signaling, severity of illness, and organ dysfunction in sepsis. Crit Care (2010) 1.72
Antioxidant intervention blunts renal injury in experimental renovascular disease. J Am Soc Nephrol (2004) 1.70
Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation (1996) 1.67
T-cell receptor signal transmission: who gives an ITAM? Trends Immunol (2003) 1.66
Delayed ascorbate bolus protects against maldistribution of microvascular blood flow in septic rat skeletal muscle. Crit Care Med (2005) 1.64
Reduction of resuscitation fluid volumes in severely burned patients using ascorbic acid administration: a randomized, prospective study. Arch Surg (2000) 1.63
Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood (2010) 1.56
Errors in the approval process and post-marketing evaluation of drotrecogin alfa (activated) for the treatment of severe sepsis. Lancet Infect Dis (2009) 1.55
Long-term vitamin C treatment increases vascular tetrahydrobiopterin levels and nitric oxide synthase activity. Circ Res (2003) 1.54
Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB. Crit Care Med (2002) 1.54
Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin. J Biol Chem (2000) 1.52
The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care (2009) 1.52
Lipid peroxidation, free radical production and antioxidant status in breast cancer. Breast Cancer Res Treat (2000) 1.51
Neutrophils kill pulmonary endothelial cells by a hydrogen-peroxide-dependent pathway. An in vitro model of neutrophil-mediated lung injury. Am Rev Respir Dis (1984) 1.50
Pretreatment plasma fibrinogen level correlates with tumor progression and metastasis in patients with squamous cell carcinoma of the esophagus. J Gastroenterol Hepatol (2007) 1.46
Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesis. Proc Natl Acad Sci U S A (2010) 1.46
Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res (1991) 1.44
The systemic pro-inflammatory response in sepsis. J Innate Immun (2010) 1.43
Intravenously administered vitamin C as cancer therapy: three cases. CMAJ (2006) 1.43
Chronic inflammation and CD16+ natural killer cell zeta-chain downregulation in hemodialysis patients. Blood Purif (2008) 1.43
Sustained levels of ascorbic acid are toxic and immunosuppressive for human T cells. P R Health Sci J (1996) 1.42
Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation (1999) 1.41
Vitamin C improves endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol (1998) 1.37
T cell receptor stimulation, reactive oxygen species, and cell signaling. Free Radic Biol Med (2004) 1.36
Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. Med Hypotheses (1995) 1.36
C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J (2009) 1.34
Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol Immunother (2004) 1.34
Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. Circulation (1997) 1.34
Defective TCR-mediated signaling in synovial T cells in rheumatoid arthritis. J Immunol (1997) 1.34
Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood (1985) 1.33
Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res (1995) 1.33
Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med (2009) 1.31
Vitamin C suppresses TNF alpha-induced NF kappa B activation by inhibiting I kappa B alpha phosphorylation. Biochemistry (2002) 1.30
Neopterin, a prognostic marker in human malignancies. Cancer Lett (2009) 1.28
Exosomes as a tumor immune escape mechanism: possible therapeutic implications. J Transl Med (2008) 1.28
Activated protein C utilizes the angiopoietin/Tie2 axis to promote endothelial barrier function. FASEB J (2009) 1.27
Cancer cachexia. Curr Opin Gastroenterol (2010) 1.27
Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci U S A (1985) 1.27
Vitamin C inhibits NF-kappa B activation by TNF via the activation of p38 mitogen-activated protein kinase. J Immunol (2000) 1.26
Recruitment of neutrophils in the local endotoxin response: association with de novo endothelial expression of endothelial leukocyte adhesion molecule-1. Lab Invest (1991) 1.26
Increased oxidative/nitrosative stress and decreased antioxidant enzyme activities in prostate cancer. Clin Biochem (2009) 1.24
Selective blockade of endothelial NF-kappaB pathway differentially affects systemic inflammation and multiple organ dysfunction and injury in septic mice. J Pathol (2010) 1.22
Disseminated intravascular coagulation in trauma patients. Semin Thromb Hemost (2001) 1.21
Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study. Oncologist (2009) 1.19
Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. Crit Care Med (1996) 1.19
Severe hypovitaminosis C in lung-cancer patients: the utilization of vitamin C in surgical repair and lymphocyte-related host resistance. Br J Cancer (1982) 1.19
The coagulant response in sepsis and inflammation. Hamostaseologie (2010) 1.17
Activated protein C for severe sepsis. N Engl J Med (2002) 1.17
Inhibition of NF-kappa B and oxidative pathways in human dendritic cells by antioxidative vitamins generates regulatory T cells. J Immunol (2005) 1.15
Total vitamin C, ascorbic acid, and dehydroascorbic acid concentrations in plasma of critically ill patients. Am J Clin Nutr (1996) 1.14
T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma. Gut (1997) 1.14
Vitamins reverse endothelial dysfunction through regulation of eNOS and NAD(P)H oxidase activities. Hypertension (2003) 1.09
Ascorbyl radical formation in patients with sepsis: effect of ascorbate loading. Free Radic Biol Med (1996) 1.09
Anti-inflammatory effects of different drugs/agents with antioxidant property on endothelial expression of adhesion molecules. Cardiovasc Hematol Disord Drug Targets (2006) 1.07
Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. J Cell Biochem (2006) 1.07
Activation of endothelial intrinsic NF-{kappa}B pathway impairs protein C anticoagulation mechanism and promotes coagulation in endotoxemic mice. Blood (2009) 1.07
Oxidation of tetrahydrobiopterin by biological radicals and scavenging of the trihydrobiopterin radical by ascorbate. Free Radic Biol Med (2002) 1.07
Ascorbic acid dynamics in the seriously ill and injured. J Surg Res (2003) 1.07
Thrombosis risk and survival in cancer patients with elevated C-reactive protein. J Thromb Haemost (2011) 1.05
Down-regulation of the T cell receptor CD3 zeta chain in rheumatoid arthritis (RA) and its influence on T cell responsiveness. Clin Exp Immunol (2000) 1.05
Vitamin C and E prevent lipopolysaccharide-induced apoptosis in human endothelial cells by modulation of Bcl-2 and Bax. Eur J Pharmacol (1996) 1.05
The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer. BJU Int (2008) 1.05
Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib. J Clin Oncol (2008) 2.38
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist (2008) 2.22
Endometrial regenerative cells: a novel stem cell population. J Transl Med (2007) 2.19
Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood (2009) 2.14
West Nile virus-associated encephalitis in recipients of renal and pancreas transplants: case series and literature review. Clin Infect Dis (2004) 1.84
The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. J Biol Chem (2007) 1.82
Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol (2004) 1.81
Embryonic stem cell marker expression pattern in human mesenchymal stem cells derived from bone marrow, adipose tissue, heart and dermis. Stem Cell Rev (2009) 1.72
Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72
Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature. Br J Haematol (2011) 1.69
Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. J Transl Med (2009) 1.62
Signaling events for metallothionein induction. Mutat Res (2003) 1.60
Systemic lupus erythematosus associated with paclitaxel use in the treatment of ovarian cancer. South Med J (2008) 1.58
Cutaneous sarcoidosis and malignancy: An association between sarcoidosis with skin manifestations and systemic neoplasia. Dermatol Online J (2011) 1.49
Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol (2009) 1.46
Interleukin-2 is present in human blood vessels and released in biologically active form by heparanase. Immunol Cell Biol (2011) 1.45
Polycystic ovary syndrome: focus on platelets and prothrombotic risk. South Med J (2011) 1.44
Intrinsic immune alterations in renal cell carcinoma and emerging immunotherapeutic approaches. Expert Opin Biol Ther (2013) 1.44
Malignant melanoma in pigmented skin: does the current interventional model fit a different clinical, histologic, and molecular entity? Dermatol Surg (2013) 1.41
Immunotherapy and prostate cancer. Cancer Treat Rev (2003) 1.40
Inflammatory and immune-related conditions associated with Waldenström macroglobulinemia: a single center experience. Leuk Lymphoma (2014) 1.39
H. pylori-associated gastric cancer in a husband-wife pair: a veritable family affair. South Med J (2009) 1.38
The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo. PLoS One (2011) 1.37
Melanocyte function and its control by melanocortin peptides. J Histochem Cytochem (2002) 1.32
Exosomes as a tumor immune escape mechanism: possible therapeutic implications. J Transl Med (2008) 1.28
Allogeneic endometrial regenerative cells: an "Off the shelf solution" for critical limb ischemia? J Transl Med (2008) 1.27
Tangeretin and nobiletin induce G1 cell cycle arrest but not apoptosis in human breast and colon cancer cells. Cancer Lett (2007) 1.25
Exosome removal as a therapeutic adjuvant in cancer. J Transl Med (2012) 1.24
Behavioral factors of patients before and after diagnosis with melanoma: a cohort study - are sun-protection measures being implemented? Melanoma Res (2010) 1.22
Mesenchymal stem cells as anti-inflammatories: implications for treatment of Duchenne muscular dystrophy. Cell Immunol (2010) 1.19
Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol Blood Marrow Transplant (2003) 1.18
Orthomolecular oncology review: ascorbic acid and cancer 25 years later. Integr Cancer Ther (2005) 1.15
Feasibility investigation of allogeneic endometrial regenerative cells. J Transl Med (2009) 1.10
Safety evaluation of allogeneic umbilical cord blood mononuclear cell therapy for degenerative conditions. J Transl Med (2010) 1.09
Feasibility of combination allogeneic stem cell therapy for spinal cord injury: a case report. Int Arch Med (2010) 1.09
Distinct patterns of chromonychia, Beau's lines, and melanoderma seen with vincristine, adriamycin, dexamethasone therapy for multiple myeloma. Dermatol Online J (2006) 1.09
A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J (2005) 1.08
Peripheral blood immunophenotypic analysis as a diagnostic tool for large granular lymphocyte leukemia. Leuk Lymphoma (2012) 1.07
A case of polycythemia rubra vera transforming into chronic phase JAK2 V617F mutation-negative Philadelphia chromosome-positive chronic myelogenous leukemia. Leuk Lymphoma (2013) 1.06
New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines. Transplantation (2005) 1.06
Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference. J Immunol (2006) 1.05
Risk factors for gallbladder cancer and cholangiocarcinoma: similarities, differences and updates. J Gastrointest Cancer (2012) 1.05
Dendritic cell activating peptides induce distinct cytokine profiles. Int Immunol (2006) 1.05
Risk for second nonlymphoid neoplasms in chronic lymphocytic leukemia. MedGenMed (2007) 1.04
Incidence of second primary malignancies in patients with esophageal cancer: a comprehensive review. Curr Med Res Opin (2013) 1.03
Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature. J Hematol Oncol (2010) 1.03
Association between Helicobacter pylori infection and pancreatic cancer. A cumulative meta-analysis. JOP (2011) 1.03
Detection of circulating tumor cells in advanced head and neck cancer using the CellSearch system. Head Neck (2011) 1.02
Manufacturing, characterization and control of cell-based medicinal products: challenging paradigms toward commercial use. Regen Med (2015) 1.02
Tumor vaccines in 2010: need for integration. Cell Immunol (2010) 1.02
Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion. Cancer Chemother Pharmacol (2008) 1.01
PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses. Int J Nanomedicine (2012) 1.01
Toxicology of antisense therapeutics. Toxicol Appl Pharmacol (2004) 1.00
Practices, attitudes, and beliefs associated with complementary and alternative medicine (CAM) use among cancer patients. Integr Cancer Ther (2012) 0.99
Characterization of human skin-derived mesenchymal stem cell proliferation rate in different growth conditions. Cytotechnology (2009) 0.99
Efficacy of the oxygen-charged static two-layer method for short-term pancreas preservation and islet isolation from nonhuman primate and human pancreata. Cell Transplant (2002) 0.99
ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside. J Hematol Oncol (2009) 0.97
A Pilot Study Comparing HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas by Whole Exome Sequencing. ISRN Oncol (2012) 0.97
Mass spectrometric studies on epigenetic interaction networks in cell differentiation. J Biol Chem (2011) 0.96
PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy. PLoS One (2011) 0.96
Intravenous ascorbic acid: protocol for its application and use. P R Health Sci J (2003) 0.96
Endometrial regenerative cells for treatment of heart failure: a new stem cell enters the clinic. J Transl Med (2013) 0.96
Lasers, stem cells, and COPD. J Transl Med (2010) 0.95
Pharmacokinetics of vitamin C: insights into the oral and intravenous administration of ascorbate. P R Health Sci J (2008) 0.95
Intravenous vitamin C as a chemotherapy agent: a report on clinical cases. P R Health Sci J (2004) 0.95
High frequency of activating PIK3CA mutations in human papillomavirus-positive oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg (2013) 0.95
Regulatory evaluation of Glybera in Europe - two committees, one mission. Nat Rev Drug Discov (2013) 0.94
Does HPV type affect outcome in oropharyngeal cancer? J Otolaryngol Head Neck Surg (2013) 0.94
Placental mesenchymal and cord blood stem cell therapy for dilated cardiomyopathy. Reprod Biomed Online (2008) 0.93
Frequent mutations in TP53 and CDKN2A found by next-generation sequencing of head and neck cancer cell lines. Arch Otolaryngol Head Neck Surg (2012) 0.93
Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting: lessons learned from first clinical trials. Transplantation (2013) 0.93